关于先锋

Company Profile

Research cooperation

Research trends

Research strength

Bioequivalence Study of Orlistat Capsules in Human

Release time:

2023-07-12

Indications:

For the treatment of overweight (body mass index > 24) adults aged 18 and over. When using this product, it should be combined with a low-calorie and low-fat diet

Test group:

1

End point indicators:

1

 

Serial number

Enterprise

Number of subjects

1

Anhui Pioneer Pharmaceutical Co., Ltd.

72 cases

2

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

90 cases

3

Zhongshan Wanhan Pharmaceutical Co., Ltd.

90 cases

4

Zeen Biotechnology Co., Ltd.

96 cases

5

Shandong New Times Pharmaceutical Co., Ltd.

84 cases
Back →

Related news

2023-07-25

Generic drug development field

2023-07-12

Bioequivalence Study of Oseltamivir Phosphate Capsules in Human

2023-07-12

Study on Bioequivalence of Lamotrigine Dispersible Tablets in Human

2023-07-12

Bioequivalence Study of Sildenafil Citrate Orally Disintegrating Tablets in Human

2023-07-12

Bioequivalence Study of Fenofibrate Capsules in Human